glp-1 and bipolar Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine Glp-1 meds and bipolar: any

The disadvantage is the metabolic disruption of stopping and starting, which may reduce the efficiency of subsequent treatment courses

NHS vs Private Access: NHS access is limited, mostly for type 2 diabetes or severe obesity with comorbidities

Multiple studies indicate that GLP-1 therapy can reduce elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levelskey biomarkers of hepatocellular injury

Is anxiety more common with semaglutide or tirzepatide

In the present work, we studied the applicability of SURFASA score in a retrospective cohort of children with severe autoimmune hepatitis to predict steroid response